The Clinical Research Glossary: New Words, New Opportunities

Webinar

Presented on: April 2, 2024

With over 160 definitions, including images and supportive information, the Clinical Research Glossary has been designed to support the communication of clear research information, along with tailored, shareable images to foster engagement and understanding.

Learn more about:

  • Building trust and transparency with participants through plain language information sharing.
  • The dedicated team members, and robust process that is followed, to create this global standard.
  • Strategies and approaches to implement the Clinical Research Glossary content into patient-facing materials. 

Related Resources


Ethical Considerations in Decentralized Clinical Trials

Publication

Published on: March 1, 2024

Published inJournal of Bioethical Inquiry

Description: Barbara Bierer and Sarah White summarized salient ethical issues in the design and conduct of decentralized clinical trials, including participant safety, privacy and confidentiality, consent, digital access and proficiency, and trial oversight. Given the increasing involvement of decentralized study components, it is necessary to develop processes and cooperative solutions to promote safe, ethical trials, as well as focus on decreasing burden and increasing access for all participants.

Joint Task Force for Clinical Trial Competency (JTF) Biannual Global Meeting

June 6, 2024 @ 9:00 am 11:00 am

Virtual Event

Details: The Joint Task Force for Clinical Trial Competency (JTF), anchored at the MRCT Center, is dedicated to developing and disseminating standards and practices for the clinical research workforce. The JTF fosters a cohesive, global approach to ensuring that professionals have the necessary competencies to conduct clinical trials effectively and ethically.

The public is invited to attend virtual biannual meetings, which happen twice a year.

Meeting Details: The meeting included information about a comprehensive training program in Canada based on the JTF Framework and other updates. There will also be a time for open discussion with meeting participants.

Key Topics:

  • Cantrain: The Canadian Consortium of Clinical Trial Training
  • CIOMS Update
  • Updates:  Deploying the JTF Framework around the World: Arabic Translation
  • 3CTN Updates
  • How a competency-based program will contribute to early clinical research professionals’ training

REACH: Advancing DEI in Human Participant Research

Webinar

Presented on: March 7, 2024

Introducing Research Ethics Action Collaborative for HRPPs (REACH), an initiative spearheaded by the MRCT Center, AAHRPP, PRIM&R, and Mass General Brigham to curate, align, and disseminate tools to advance access to and inclusion in research—for all potential participants–tailored for Institutional Review Boards (IRBs), Human Research Protection Programs (HRPPs), and the broader community. 

We Need Your Voice:
Your perspective is invaluable to us. Help guide our efforts to improve research access and inclusion by sharing your thoughts via our brief survey. Your feedback is critical in shaping the tools and resources we develop and disseminate.

Related Resources

Panelist Biographies
List of resources shared during the webinar
Questions & Answers
Survey

Global Representation: An Introduction to the Global Representation Project

Introduction


The MRCT Center’s Achieving Diversity, Inclusion, and Equity in Clinical Research Guidance Document, released in late 2020 and updated in 2021, outlines a principled, multi-stakeholder approach to optimize the inclusion of diverse populations in clinical research. It is accompanied by a Toolkit, including checklists, logic models and case studies, an Equity by Design metrics framework, and resources to support ethics committees. These are all living documents, and further work, such as the inclusion of people with disabilities in clinical research, is ongoing.

As part of this further work, the MRCT Center has widened our DEI lens from domestic to Global Representation. Over the last nine months, we have collaboratively sought to better understand how concerns around diversity, equity, and inclusion in clinical research are understood and prioritized in different countries and regions around the world and what this means for the many stakeholders involved in research conducted in multi-country contexts. We have several tools under development, including a draft Roadmap (prompts for developing a global diversity, equity, inclusion, and accessibility strategy) introduced during the [invite-only] Executive and Steering Committees meeting in December and a Diversity Action Plan (DAP) tool presented at the MRCT Annual Meeting.  

The primary objectives of this project encompass a comprehensive exploration of DEI challenges within the domain of global clinical research. These objectives are two-fold.

  1. The project is focused on a deeper comprehension of DEI issues in clinical research on a global scale. This entails seeking insights from key stakeholders such as sponsors, regulators, ethics committees, health departments, Principal Investigators (PIs), study sites, and research participants.
  2. The project is working on enhancing and expanding the existing resources and tools provided by the MRCT Center to incorporate these broader perspectives. This expansion includes supporting DEI in research endeavors within individual countries and, notably, in multi-country studies.

The preliminary scoping of the first objective has brought to light several areas of focus encompassing: the recognition that different dimensions of diversity hold varying degrees of relevance in diverse global contexts; the challenges of categorizing diversity facets like race, ethnicity, and social determinants of health in ways that remain contextually meaningful in various countries; ethical concerns related to incentivizing the participation of groups traditionally viewed as ‘vulnerable’ in research, along with associated risks of exploitation; divergent approaches of regulators worldwide regarding diversified participation in research, both in terms of licensing requirements and the endorsement of best practices; and varying motivations for addressing DEI at a global level, ranging from ethical considerations regarding broader generalizability and global access to interventions to more immediate needs for compliance with regulatory mandates in different regions.

In essence, the project seeks to synthesize these multifaceted elements into a unified strategy that addresses DEI challenges in the global clinical research landscape.

We have been drafting four principal tools:

  • A Draft Roadmap: Prompts for Developing a global diversity, equity, inclusion, and accessibility (DEI) strategy
  • Embedding Ethical Considerations related to global DEI
  • Working with Partner Countries to Strengthen Research Capacity
  • Diversity Action Plan (DAP) Template

If you would like to share relevant resources or insights, please contact us here.

Real World Evidence (RWE) and Emerging Trends in Clinical Trial Subject Recruitment

May 3, 2024 @ 1:30 pm 4:00 pm

Hybrid: In-person (Boston) and Virtual (Zoom)

800 Boylston St.
Boston, MA 02199

Meeting of The Research, Development, and Regulatory Roundtable (R3). Meetings are open to R3 Sponsors. To learn more about how to become an R3 Sponsor, click here.

Topics:

  • Recent Developments in FDA Guidance on Real World Evidence
  • Subject-Directed Recruitment Materials and Testimonials

Abstract: Real World Evidence and Emerging Trends in Clinical Trial Subject Recruitment

Real World Evidence

In recent years, real-world evidence (“RWE”) has increasingly been incorporated into product development programs, spurred by greater access to RWE, legislative changes, and significant policy development at FDA. The use of RWE raises novel opportunities, as well as new challenges for regulators, clinical trial sponsors, and the life sciences and healthcare industry to set common standards for RWE to ensure it can be relied upon with confidence in regulatory decision-making.  

During 2023, FDA released two draft and three final guidance documents concerning RWE.  These included the following:

  •  Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products (Draft, February 2023)
  • Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (Final, August 2023)
  • Use of Real-World Evidence to Support Regulatory Decision-Marking for Medical Devices (Draft, December 2023)
  • Data Standards for Drug and Biological Product Submissions Containing Real World Data (Final, December 2023)
  • Real-World Data:  Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products (Final, December 2023) 

This session will provide an overview of key concepts from these guidance documents, focusing in particular on how they intersect with FDA’s existing regulations on clinical investigations and how they may change the regulatory landscape.  In addition to focusing on these recent FDA guidance documents, the speakers will address the application of other U.S. regulatory regimes to RWE activities, including the Common Rule, the Information Blocking Rule, and HIPAA and other data privacy laws.

Clinical Trial Subject Recruitment Trends

Clinical trial sponsors are increasingly exploring different techniques to attract potential subjects to clinical trials, particularly in the context of rare disease studies for which subjects may be difficult to find.  These techniques have included the following:

  •  Use of testimonials featuring active clinical trial subjects in clinical trial advertisements
  •  Inclusion of detailed scientific information gathered in pre-clinical or Phase 1 studies in subject-directed recruitment materials
  • Partnerships with electronic health record vendors to identify potential trial sites or subjects

Each of these techniques raise novel regulatory questions, including concerns about pre-approval promotion, data bias, need for institutional review board review and approval, and data privacy.  

This session will analyze these trends and the attendant regulatory considerations for each.